Murray Cian P, Kenny Andrew P, O'Sullivan Niall J, Murphy Ross T, Curtain James P
Department of Cardiology, St. James's Hospital, Dublin, Ireland.
Front Cardiovasc Med. 2025 Aug 11;12:1612545. doi: 10.3389/fcvm.2025.1612545. eCollection 2025.
Heart failure (HF) hospitalizations are prognostically significant. Implantable hemodynamic monitors detect early congestion but are invasive and costly, with no clear mortality benefit. Wearable devices offer a non-invasive alternative for monitoring congestion. This meta-analysis examines the efficacy of wearable devices in reducing HF hospitalizations and mortality compared to standard care.
A systematic review and meta-analysis were conducted following PRISMA guidelines. PubMed, EMBASE, MEDLINE, and Cochrane databases were searched for trials comparing wearable device-guided care with standard HF treatment. Outcomes included hospitalisation for HF, worsening HF events (hospitalisation or emergency department visit for HF) and all-cause mortality. Total (first and recurrent) event meta-analyses were performed using random effect models.
Four studies met inclusion criteria, including 958 patients who were enrolled either at the time of or within 10 days of discharge from a hospitalization for HF. Wearable device-guided care resulted in a 41% reduction in hospitalisations for HF (RR: 0.59, 95% CI: 0.41-0.87, = 0.007) and a 40% reduction in HF events (RR: 0.60, 95% CI: 0.42-0.86, = 0.005) compared to standard care. All-cause mortality was reduced by 26% in the wearable monitoring arm (RR: 0.74, 95% CI: 0.55-0.99, = 0.04). The composite outcome of HF hospitalization and mortality was 37% lower with wearable monitoring (RR: 0.63, 95% CI: 0.44-0.91, = 0.04). Treatment for HF, guided by wearable devices that measure pulmonary congestion, reduced hospitalisations for HF and all-cause mortality in recently hospitalised patients.
Wearable devices are a promising non-invasive strategy for managing high-risk patients, particularly when transitioning care from acute to community settings..
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024607770, identifier PROSPERO CRD42024607770.
心力衰竭(HF)住院具有重要的预后意义。植入式血流动力学监测器可检测早期充血情况,但具有侵入性且成本高昂,且未显示出明显的降低死亡率的益处。可穿戴设备为监测充血提供了一种非侵入性替代方法。本荟萃分析探讨了与标准治疗相比,可穿戴设备在减少HF住院和死亡率方面的疗效。
按照PRISMA指南进行系统评价和荟萃分析。检索了PubMed、EMBASE、MEDLINE和Cochrane数据库,以查找比较可穿戴设备指导护理与标准HF治疗的试验。结局包括HF住院、HF病情恶化事件(因HF住院或就诊于急诊科)和全因死亡率。使用随机效应模型进行总(首次和复发)事件荟萃分析。
四项研究符合纳入标准,包括958例在HF住院时或出院后10天内入组的患者。与标准护理相比,可穿戴设备指导护理使HF住院率降低了41%(RR:0.59,95%CI:0.41-0.87,P=0.007),HF事件减少了40%(RR:0.60,95%CI:0.42-0.86,P=0.005)。可穿戴监测组的全因死亡率降低了26%(RR:0.74,95%CI:0.55-0.99,P=0.04)。HF住院和死亡率的综合结局在可穿戴监测组降低了37%(RR:0.63,95%CI:0.44-0.91,P=0.04)。由测量肺充血的可穿戴设备指导的HF治疗,降低了近期住院患者的HF住院率和全因死亡率。
可穿戴设备是管理高危患者的一种有前景的非侵入性策略,特别是在从急性护理过渡到社区护理时。
https://www.crd.york.ac.uk/PROSPERO/view/CRD42024607770,标识符PROSPERO CRD42024607770。